TEMPO EXCLUSIVE
Tempo English
SUBSCRIBE

COVID-19: Indofarma to Produce Ivermectin in July

Translator

Ricky Mohammad Nugraha

Editor

Markus Wisnu Murti

2 July 2021 15:53 WIB

Ivermectin. Brazilian Report

TEMPO.CO, Jakarta - State-owned pharmaceutical firm PT Indofarma on Friday spoke about Ivermectin that has recently claimed popularity after a number of public figures claimed the drug's effectiveness against COVID-19. 

Asked by Tempo about the price for one pack, Indofarma management stated in a written release on Friday, July 2, that they “established the price for [Ivermectin] at Rp123 thousand.”

The product they sell includes 20 tablets of 12 mg per botol. The highest retail price that includes the added-value tax (PPN) is set at Rp157,700 (US$10 in current exchange). 

Based on Tempo’s observation across online and physical stores the drug is sold at an average price of Rp200,000 (US$13.7) with the highest retail price at Rp256,000 (US$ 17). 

Ivermectin, as of June 20, has obtained marketing authorization from the Food and Drugs Monitoring Agency (BPOM). Indofarma stated the production of the drug would kickstart in early July, and that it aimed at producing 13.8 million tablets until August 2021. 

Read: Ivermectin as COVID-19 Treatment to Be Priced at Rp5,000-7,000 per Tablet

SYAHARANI PUTRI

IvermectinIndofarmaCOVID-19


Recommended

China's COVID-19 Emergency Has Peaked, Official Says

13 jam lalu

China's COVID-19 Emergency Has Peaked, Official Says

Coronavirus fever and emergency hospitalizations have peaked in China and the number of hospitalized Covid-19 patients is continuing to decline.


2022 Car Sales Reach 1 Million Units, Up by 17.4 Percent

1 hari lalu

2022 Car Sales Reach 1 Million Units, Up by 17.4 Percent

Car sales in Indonesia have increased as the economic condition improved after the Covid-19 outbreak subsided


Yogyakarta Covid-19 Case Enters the Lowest Phase in Early 2023, Tourist Visits Decreasing

4 hari lalu

Yogyakarta Covid-19 Case Enters the Lowest Phase in Early 2023, Tourist Visits Decreasing

The new case of Covid-19 in the region of Yogyakarta in early January 2023 was recorded to have entered the lowest phase of its spreading.


Nataru Holidays Ended, Covid-19 Cases in Yogyakarta Dropped by Half

10 hari lalu

Nataru Holidays Ended, Covid-19 Cases in Yogyakarta Dropped by Half

The end of the Christmas and New Year (Nataru) holidays does not always necessarily conclude with an increase in Covid-19 cases in Yogyakarta.


YLKI Speaks of State Health Insurance Covering Covid-19 Post-PPKM

12 hari lalu

YLKI Speaks of State Health Insurance Covering Covid-19 Post-PPKM

Covid-19 will reportedly be covered by the BPJS Kesehatan after the coronavirus restriction was lifted by the government last year.


Revoking PPKM is a Wise Choice, Observer Says

12 hari lalu

Revoking PPKM is a Wise Choice, Observer Says

Policy observer from Jenderal Soedirman University (Unsoed), Professor Slamet Rosyadi, said that the revocation of PPKM is a wise decision.


PPKM Revoked, RIdwan Kamil: People Must be Wise

12 hari lalu

PPKM Revoked, RIdwan Kamil: People Must be Wise

West Java Governor Ridwan Kamil, said that with the revocation of the PPKM policy, the public must be wise in maintaining awareness against Covid-19.


PPKM Stopped, Yogyakarta Continue to Monitor Public Mobilization

12 hari lalu

PPKM Stopped, Yogyakarta Continue to Monitor Public Mobilization

Following the recent revocation of the Public Activity Restriction (PPKM) policy, Yogyakarta regional government continues to monitor the public.


Luhut on PPKM: Health Emergency Still in Effect

12 hari lalu

Luhut on PPKM: Health Emergency Still in Effect

Minister Luhut Pandjaitan says that vaccination activities should not be lessened, let alone stopped after the PPKM policy is revoked.


The Dynamics Behind Lifting Coronavirus Social Restriction, PPKM

13 hari lalu

The Dynamics Behind Lifting Coronavirus Social Restriction, PPKM

President Jokowi lifted the coronavirus social restriction or PPKM on December 30th. Here is what the general public needs to consider.